{"id":"W4220900778","doi":"10.1158/1538-7445.sabcs21-p1-18-03","title":"Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Rash; Internal medicine; Maculopapular rash; Letrozole; Clinical endpoint; Cohort; Oncology; Cancer; Hazard ratio; Breast cancer; Adverse effect; Confidence interval; Clinical trial; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001649628,0.0006319234,0.001142436,0.0002820862,0.000358533,0.001051831,0.0006171325,0.0007298068,0.003759078],"category_scores_gemma":[0.001504533,0.0002731851,0.001878162,0.0003701594,0.0003765962,0.0007716866,0.0005049919,0.002113912,0.0007078794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008727679,"about_ca_system_score_gemma":0.001208284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001901638,"about_ca_topic_score_gemma":0.002761868,"domain_scores_codex":[0.9994285,0.0002090933,0.00003380753,0.0001587571,0.000077342,0.00009245915],"domain_scores_gemma":[0.9985161,0.0002154099,0.0004279902,0.0001488971,0.0001507192,0.0005408407],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7781351,0.01152427,0.1242364,0.0004014499,0.003563204,0.0002248218,0.0001786572,0.001151523,0.007705774,0.0001383115,0.007550017,0.06519051],"study_design_scores_gemma":[0.2089676,0.340215,0.4230434,0.0002279867,0.005384297,0.0007810856,0.0003145328,0.00329934,0.006273758,0.0005022889,0.01089905,0.000091744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919241,0.0009775361,0.000254678,0.0002737445,0.00005321654,0.0004320885,0.004891814,0.00003999175,0.001152878],"genre_scores_gemma":[0.9856576,0.0006353068,0.0004366229,0.0004620058,0.0001072973,0.0005286864,0.01071628,0.00002099346,0.001435096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003759078,"threshold_uncertainty_score":0.01257539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02095730569695405,"score_gpt":0.3205103256317687,"score_spread":0.2995530199348146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}